NASDAQ:BCTXW BriaCell Therapeutics (BCTXW) Stock Price, News & Analysis $0.11 -0.02 (-12.91%) As of 02/21/2025 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends About BriaCell Therapeutics Stock (NASDAQ:BCTXW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's Range$0.10▼$0.1250-Day Range$0.11▼$0.3552-Week Range$0.08▼$1.89Volume12,609 shsAverage Volume112,894 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More… Receive BCTXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCTXW Stock News HeadlinesBriaCell regains Nasdaq compliance with bid priceFebruary 13, 2025 | msn.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingFebruary 5, 2025 | financialpost.com$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.February 22, 2025 | Altimetry (Ad)BriaCell Completes 15:1 Share Consolidation for Nasdaq ComplianceJanuary 27, 2025 | tipranks.comBriaCell Therapeutics Corp.: BriaCell Announces Proposed Effective Date of Share ConsolidationJanuary 5, 2025 | finanznachrichten.deBriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast CancerDecember 13, 2024 | finance.yahoo.comBriaCell Therapeutics Faces Uncertain Financial FutureNovember 2, 2024 | markets.businessinsider.comBriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast CancerJuly 21, 2024 | stockhouse.comSee More Headlines BCTXW Stock Analysis - Frequently Asked Questions How have BCTXW shares performed this year? BriaCell Therapeutics' stock was trading at $0.2895 at the beginning of the year. Since then, BCTXW stock has decreased by 61.3% and is now trading at $0.1120. View the best growth stocks for 2025 here. How do I buy shares of BriaCell Therapeutics? Shares of BCTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCTXW CUSIPN/A CIK1610820 WebN/A Phone604-921-1810FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:BCTXW) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
